RE:little bit on the FDA for 2017 all is relative,as share holder of pli ,we see this article in a different way.
the FDA for the case of perfenidone was not so wrong by the fact that we ,now, know the weak response of patient for this drug.
Don,t forget ,the FDA ask prometic specificly to compare pbi4050 with perfenidone.
They have an idea and i think it is to discard perfenidone as soon aS POSSIBLE.